Logotype for Denali Therapeutics Inc

Denali Therapeutics (DNLI) investor relations material

Denali Therapeutics Stifel 2025 Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Denali Therapeutics Inc
Stifel 2025 Healthcare Conference summary12 Nov, 2025

Strategic vision and technology

  • Focused on crossing the blood-brain barrier and defeating neurodegeneration using transport vehicle technology, leveraging transferrin receptor for CNS delivery.

  • Pipeline progress includes late-stage and new clinical programs, with regulatory filings for multiple modalities.

  • Three main franchises: enzyme transport vehicle (ETV), oligonucleotide, and protein replacement therapies.

  • ETV franchise includes programs for Hunter syndrome (BLA under review), Sanfilippo (accelerated approval planned), Pompe (entering trials), and FTD granulin.

  • First oligonucleotide program targeting MAPT (tau) has entered the clinic, with an amyloid beta program close to filing.

Regulatory and clinical updates

  • Hunter syndrome BLA review delayed by FDA due to a clerical error, shifting PDUFA date to April 5, but engagement remains positive and collaborative.

  • Launch preparations underway with a small, ready field team for Hunter and Sanfilippo, with plans to expand for Pompe.

  • Market access strategy divides global opportunity into thirds: US, ex-US accessible with accelerated approval, and Europe requiring additional clinical endpoints.

  • Sanfilippo program completed Phase 1/2 enrollment (20 patients), with data expected 49 weeks post-September and BLA filing preparation underway.

  • Sanfilippo manufacturing is in-house, marking a shift from previous reliance on external partners.

Clinical data and trial design

  • Robust biomarker effects observed in Sanfilippo and Hunter programs, with neurocognitive, behavioral, and hearing data maturing.

  • Hunter confirmatory trial uses active comparator and co-primary endpoints of CSF heparan sulfate and Vineland behavioral scale; enrollment to complete by year-end, with trial completion expected in 2027.

  • Sanfilippo trial likely to use natural history as comparator due to lack of standard of care, with similar endpoints as Hunter.

  • Pompe program addresses unmet needs in both neuro and muscle domains, with further strategy details to be shared at Analyst Day.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Denali Therapeutics earnings date

Logotype for Denali Therapeutics Inc
Jefferies London Healthcare Conference 202518 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Denali Therapeutics earnings date

Logotype for Denali Therapeutics Inc
Jefferies London Healthcare Conference 202518 Nov, 2025

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Denali Therapeutics Inc is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company researches and creates treatments targeting conditions such as Alzheimer's disease, Parkinson’s disease, and other disorders affecting the central nervous system. Denali Therapeutics operates within the healthcare and biotechnology sectors. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage